RIS ID

115987

Publication Details

Tharmalingam, N., Jayamani, E., Rajamuthiah, R., Castillo, D., Fuchs, B. Burgwyn., Kelso, M. J. & Mylonakis, E. (2017). Activity of a novel protonophore against methicillin-resistant Staphylococcus aureus. Future Medicinal Chemistry, 9 (12), 1401-1411.

Abstract

Aim: Compound 1-(4-chlorophenyl)-4,4,4-trifluoro-3-hydroxy-2-buten-1-one (compound 1) was identified as a hit against methicillin-resistant Staphylococcus aureus (MRSA) strain MW2.

Methods & results: The MIC of compound 1 against MRSA was 4 μg/ml. The compound showed enhanced activity at acidic pH by lowering bacterial intracellular pH and exhibited no lysis of human red blood cells at up to 64 μg/ml and its IC50 against HepG2 cells was 32 μg/ml. The compound reduced 1-log10 colony forming units of intracellular MRSA in macrophages and prolonged the survival of MRSA-infected Caenorhabditis elegans (p = 0.0015) and Galleria mellonella (p = 0.0002).

Conclusion: Compound 1 is a protonophore with potent in vitro and in vivo activity against MRSA and no toxicity in mammalian cells up to 8 μg/ml that warrants further investigation as a novel antibacterial.

Available for download on Friday, August 03, 2018

Share

COinS
 

Link to publisher version (DOI)

http://dx.doi.org/10.4155/fmc-2017-0047